Alembic Pharma receives USFDA approval for lung cancer drug Binimetinib ...Middle East

Business Standard - Economy

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Binimetinib tablets for treatment of lung cancer. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product, Mektovi Tablets (15 mg), of Array BioPharma Inc, the company said in a regulatory filing on Saturday. Alembic is eligible for 180 days of generic drug exclusivity for Binimetinib Tablets, 15 mg and 45 mg, as it was one of the first ANDA applicants for the 15 mg strength and the sole first applicant for the 45 mg strength to submit a substantially complete ANDA with a paragraph IV certification, the filing said. Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma and non-small cell lung cancer with a BRAF V600E mutation, it said. According to IQVIA, Binimetinib tablets have an estimat

Hence then, the article about alembic pharma receives usfda approval for lung cancer drug binimetinib was published today ( Sunday 15/11/2026 - 01:41 PM ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Alembic Pharma receives USFDA approval for lung cancer drug Binimetinib )

Last updated : 15 Nov 2026 clock 01:41 PM

Also on site :

Alembic Pharma receives USFDA approval for lung cancer drug Binimetinib ...Middle East

Winter session likely in Dec first week, govt may push women's quota bill

FAA to audit India's aviation safety oversight standards from Nov 16-20

Lutnick Pushed to Weaken Chip Rules That Overlap With His Family Business

Third-party funding may unlock ₹4.38 trillion in insolvency claims

Casi 10 000 km, 11 países, 15 paradas: la gira europea de JA concluye con éxito

Noel Tata questions big investments as $185 billion group feud deepens

Près de 10 000 km, 11 pays, 15 étapes : La tournée européenne de JA s'achève avec succès

Consumer spending on ITC's Savlon, Nimyle to double in medium term

GIFT City could become cross-border wealth booking hub: StanChart executive

Measure AI by results, not number of agents deployed: Oracle's executive

India should become developer, global leader in advanced tech: Rajnath

Scottish wealth fund ‘could be double Norway’s’ – according to economist who built it

Motherson eyes bigger India play with global technologies to drive growth

Zappfresh operator DSM Fresh Foods reports ₹7.3 crore profit in H1 FY27

Crypto's slow-motion selloff leaves investors weary as Bitcoin nears lows